• On-Demand
Navigating the Patient Journey in Chronic Lymphocytic Leukemia: Oncology Nurse Strategies in Therapy Management
  • Oncology
Click here for activity.
5
  • ANCC
  • Participation
  • Webinar recorded
New Horizons in Ovarian Cancer: Expert Insights into the Role of Genetic Biomarkers in Precision Therapy
  • Oncology
Click here for activity.
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
How Do We Identify HER2+ Gastric Cancer?
  • Gastrointestinal
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
IO Therapies in the Advanced Bladder Cancer Clinic: Aligning Your Team for Success
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
  • On-Demand
What’s the Best Approach to Select Targeted Treatments for HER2+ Gastric Cancer and What are Practical Considerations?
  • Gastrointestinal
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • AMA PRA Category 1 Credit™
  • Participation
  • Webinar recorded
2020 and Beyond: How Immunotherapy is Changing the Game in Bladder Cancer Management
  • Oncology
Please Note: Credit Is No Longer Available 
5
  • AAPA Category I CME
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
  • Webinar recorded
Focusing on the Role of the Advanced Bladder Cancer Care Team: Case Studies on Managing irAEs
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
  • Webinar recorded
Future Directions in Bladder Cancer Treatment: The Experts Weigh In
  • Oncology
Please Note: Credit Is No Longer Available 
0
  • ACPE Pharmacy
  • AMA PRA Category 1 Credit™
  • ANCC
  • Participation
  • On-Demand
How Do Antibody-Drug Conjugates (ADCs) Fit into Precision Medicine for Gastric Cancer?
  • Gastrointestinal
  • Oncology
Please Note: Credit Is No Longer AvailableAntibody-drug conjugates or “ADCs” are a novel class of highly potent biopharmaceutical drug composed of an antibody lin
0
  • AMA PRA Category 1 Credit™
  • Participation
  • On-Demand
Applying ADAURA in Practice: Implications for Early Stage EGFRm NSCLC - Medical Moment One
  • Oncology
  • Pulmonology
Please Note: Credit Is No Longer Available Medical Moment One: Expert Insight on Practical Aspects of Molecular Profiling for Early-Stage NSCLC
0
  • AMA PRA Category 1 Credit™
  • Participation

Pages